Upcoming clinical trials
A Phase I/II study to investigate the safety, biologic and anti-tumor activity of oncolytic vaccinia virus armed with a CXCR4 antagonist in combination with pembrolizumab in patients receiving liposomal doxorubicin for recurrent or treatment refractory ovarian, fallopian tube or primary peritoneal cancer (expected early 2023).
A Phase I/II trial of patient-specific neoepitope-loaded autologous dendritic cells and PD-1 blockade in advanced ovarian cancer (expected early 2024).
View a list of all ovarian cancer clinical trials offered by cancer centers across the United States.